EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multi-epitope vaccine design using in silico analysis of glycoprotein and nucleocapsid of NIPAH virus

Anoop Kumar iD, Gauri Misra, Sreelekshmy Mohandas, Pragya D Yadav

PLOS ONE · 10.05.2024 · 19 (5) · e0300507

DOI: 10.1371/journal.pone.0300507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 10.05.2024. Verfasst von Anoop Kumar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Diagnostic Laboratory, National Institute of Biologicals, Noida, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Nipah Virus, Viral Vaccines, Glycoproteins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

According to the 2018 WHO R&D Blueprint, Nipah virus (NiV) is a priority disease, and the development of a vaccine against NiV is strongly encouraged. According to criteria used to categorize zoonotic diseases, NiV is a stage III disease that can spread to people and cause unpredictable outbreaks. Since 2001, the NiV virus has caused annual outbreaks in Bangladesh, while in India it has caused occasional outbreaks. According to estimates, the mortality rate for infected individuals ranges from 70 to 91%. Using immunoinformatic approaches to anticipate the epitopes of the MHC-I, MHC-II, and B-cells, they were predicted using the NiV glycoprotein and nucleocapsid protein. The selected epitopes were used to develop a multi-epitope vaccine construct connected with linkers and adjuvants in order to improve immune responses to the vaccine construct. The 3D structure of the engineered vaccine was anticipated, optimized, and confirmed using a variety of computer simulation techniques so that its stability could be assessed. According to the immunological simulation tests, it was found that the vaccination elicits a targeted immune response against the NiV. Docking with TLR-3, 7, and 8 revealed that vaccine candidates had high binding affinities and low binding energies. Finally, molecular dynamic analysis confirms the stability of the new vaccine. Codon optimization and in silico cloning showed that the proposed vaccine was expressed to a high degree in Escherichia coli . The study will help in identifying a potential epitope for a vaccine candidate against NiV. The developed multi-epitope vaccine construct has a lot of potential, but they still need to be verified by in vitro & in vivo studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nipah VirusViral VaccinesGlycoproteinsHumansHenipavirus InfectionsComputer SimulationEpitopesMolecular Dynamics SimulationNucleocapsidMolecular Docking Simulation

Substanzen

Viral VaccinesGlycoproteinsEpitopes

Autor:innen und Institutionen

  • Molecular Diagnostic Laboratory, National Institute of Biologicals, Noida, Uttar Pradesh, India.
  • Maximum Containment Laboratory, ICMR-National Institute of Virology, Microbial Containment Complex, Pashan, Pune, India.

ORCID-Profile: Anoop Kumar

Zitieren

APA

Kumar, A., Misra, G., Mohandas, S., & Yadav, P. D. (2024). Multi-epitope vaccine design using in silico analysis of glycoprotein and nucleocapsid of NIPAH virus. PLOS ONE, 19(5), e0300507. https://doi.org/10.1371/journal.pone.0300507

Vancouver

Kumar A, Misra G, Mohandas S, Yadav PD. Multi-epitope vaccine design using in silico analysis of glycoprotein and nucleocapsid of NIPAH virus. PLOS ONE. 2024;19(5):e0300507. doi:10.1371/journal.pone.0300507

BibTeX
@article{Kumar2024,
  author = {Kumar, Anoop and Misra, Gauri and Mohandas, Sreelekshmy and Yadav, Pragya D},
  title = {Multi-epitope vaccine design using in silico analysis of glycoprotein and nucleocapsid of NIPAH virus},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {5},
  pages = {e0300507},
  doi = {10.1371/journal.pone.0300507}
}
Kostenlos starten →